Going though it now a lot seems like old news.
Post# of 157824
(Total Views: 513)
Posted On: 06/21/2023 6:30:47 PM
Going though it now a lot seems like old news.
“Dr. Ndhlovu served on the Company’s Scientific Advisory Board for a period of time. As compensation for that service, Dr. Ndhlovu was granted an option to purchase 50,000 shares of common stock with an exercise price of $3.36 per share that will expire on August 31, 2030, and an option to purchase an additional 50,000 shares of common stock with an exercise price of 0.50 per share that will expire on September 6, 2032. The awards were not subject to disclosure under Regulation S-K Item 404(a), but the Board took them into consideration in determining that Dr. Ndhlovu is independent under the Nasdaq Rules.“
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth the beneficial ownership of common stock as of May 31, 2023, by (i) beneficial owners of more than 5 percent of our outstanding shares of common stock; (ii) each of our directors; (iii) each of our named executive officers; and (iv) all of our current executive officers and directors as a group.
Amount and Nature of
Percent of
Name and Address of Beneficial Owner (1)
Beneficial Ownership (2)
Total (3)
Beneficial owners of more than 5 percent:
David F. Welch(4)
51,919,899
5.4
%
Current Directors and Executive Officers:
A. Cyrus Arman, Ph.D.(5)
869,564
—
Antonio Migliarese (6)
2,181,226
*
Scott A. Kelly, M.D.(7)
1,116,408
*
Nitya G. Ray, Ph.D.
351,545
*
Karen J. Brunke, Ph.D.(
284,611
*
Ryan C. Dunlap(
185,334
*
Lishomwa C. Ndhlovu, M.D., Ph.D.(
459,611
*
Stephen M. Simes(
178,012
*
Tanya Durkee Urbach(9)
521,724
*
All current directors and executive officers as a group (7 persons)(10)
4,680,082
0.5
%
“Dr. Ndhlovu served on the Company’s Scientific Advisory Board for a period of time. As compensation for that service, Dr. Ndhlovu was granted an option to purchase 50,000 shares of common stock with an exercise price of $3.36 per share that will expire on August 31, 2030, and an option to purchase an additional 50,000 shares of common stock with an exercise price of 0.50 per share that will expire on September 6, 2032. The awards were not subject to disclosure under Regulation S-K Item 404(a), but the Board took them into consideration in determining that Dr. Ndhlovu is independent under the Nasdaq Rules.“
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth the beneficial ownership of common stock as of May 31, 2023, by (i) beneficial owners of more than 5 percent of our outstanding shares of common stock; (ii) each of our directors; (iii) each of our named executive officers; and (iv) all of our current executive officers and directors as a group.
Amount and Nature of
Percent of
Name and Address of Beneficial Owner (1)
Beneficial Ownership (2)
Total (3)
Beneficial owners of more than 5 percent:
David F. Welch(4)
51,919,899
5.4
%
Current Directors and Executive Officers:
A. Cyrus Arman, Ph.D.(5)
869,564
—
Antonio Migliarese (6)
2,181,226
*
Scott A. Kelly, M.D.(7)
1,116,408
*
Nitya G. Ray, Ph.D.
351,545
*
Karen J. Brunke, Ph.D.(
284,611
*
Ryan C. Dunlap(
185,334
*
Lishomwa C. Ndhlovu, M.D., Ph.D.(
459,611
*
Stephen M. Simes(
178,012
*
Tanya Durkee Urbach(9)
521,724
*
All current directors and executive officers as a group (7 persons)(10)
4,680,082
0.5
%
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36